Method for treating and identifying lung cancer patients likely to benefit from EGFR inhibitor and a monoclonal antibody HGF inhibitor combination therapy
Heinrich Röder,Julia Grigorieva,May Han,Philip Komarnitsky,Jeno Gyuris
申请号：
US14678428
公开号：
US20150285817A1
申请日:
2015.04.03
申请国别(地区):
US
年份:
2015
代理人:
摘要：
A test to identify whether a lung patient is likely to benefit from combination therapy in the form of an epidermal growth factor receptor inhibitor (EGFR-I) and a monoclonal antibody drug targeting hepatocyte growth factor (HGF) as compared to EGFR-I monotherapy. The test makes use of a mass spectrum obtained from a serum or plasma sample and a computer configured as a classifier operating on the mass spectrum and a training set in the form of class-labeled mass spectra from other cancer patients. The computer classifier executes a classification algorithm, such as K-nearest neighbor, and assigns a class label to the serum or plasma sample. Samples classified as “Poor” or the equivalent are associated with patients which are likely to benefit from the combination therapy more than from EGFR-I monotherapy. The invention also includes improved methods of treating patients predicted by the test.
